These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1888828)

  • 1. Steady-state pharmacokinetics of enteric coated 5-amino-salicylic acid tablets in healthy volunteers and in patients with Crohn's disease or ulcerative colitis.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1991 Jun; 5(3):291-300. PubMed ID: 1888828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1990 Oct; 4(5):497-505. PubMed ID: 2129637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1989 Aug; 3(4):333-42. PubMed ID: 2518847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers.
    Gionchetti P; Campieri M; Belluzzi A; Boschi S; Brignola C; Miglioli M; Barbara L
    Aliment Pharmacol Ther; 1994 Oct; 8(5):535-40. PubMed ID: 7865646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease.
    Hardy JG; Healey JN; Reynolds JR
    Aliment Pharmacol Ther; 1987 Aug; 1(4):273-80. PubMed ID: 2979672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease.
    Healey JN
    Scand J Gastroenterol Suppl; 1990; 172():47-51. PubMed ID: 2353171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
    Ewe K; Becker K; Ueberschaer B
    Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
    Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scintigraphic study of gastrointestinal transit and disintegration sites of mesalazine tablets labeled with technetium-99m.
    Sciarretta G; Furno A; Mazzoni M; Ferrieri A; Malaguti P
    Scand J Gastroenterol; 1993 Sep; 28(9):783-5. PubMed ID: 8235433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.
    Mardini HA; Lindsay DC; Deighton CM; Record CO
    Gut; 1987 Sep; 28(9):1084-9. PubMed ID: 3678967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission.
    Almer S; Norlander B; Ström M; Osterwald H
    Scand J Gastroenterol; 1991 Mar; 26(3):327-35. PubMed ID: 1853156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
    Tromm A; Griga T; May B
    Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
    Rachmilewitz D
    BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine.
    Larouche J; Morais J; Picard M; Lambert C; Spénard J; Landriault H; Kennedy G; Poitras P
    Aliment Pharmacol Ther; 1995 Jun; 9(3):315-20. PubMed ID: 7654894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics.
    Klotz U; Maier KE; Fischer C; Bauer KH
    Arzneimittelforschung; 1985; 35(3):636-9. PubMed ID: 4039590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.
    Schreiber S; Howaldt S; Raedler A
    Gut; 1994 Aug; 35(8):1081-5. PubMed ID: 7926910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
    Maier K; Fischer C; Klotz U; Heinkel K
    Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?
    Nakshabendi IM; Duncan A; Russell RI
    Postgrad Med J; 1992 Mar; 68(797):189-91. PubMed ID: 1350343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
    Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
    J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.